Total Payments
$1,370
2024 Payments
$137.11
Companies
21
Transactions
75
Medicare Patients
1,265
Medicare Billing
$142,667
Payment Breakdown by Category
Food & Beverage$1,338 (97.6%)
Education$32.27 (2.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,338 | 74 | 97.6% |
| Education | $32.27 | 1 | 2.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $164.73 | 10 | $0 (2024) |
| GlaxoSmithKline, LLC. | $139.69 | 7 | $0 (2024) |
| AbbVie Inc. | $127.95 | 9 | $0 (2021) |
| Janssen Pharmaceuticals, Inc | $114.34 | 4 | $0 (2020) |
| Novo Nordisk Inc | $111.39 | 6 | $0 (2024) |
| Astellas Pharma US Inc | $111.07 | 6 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $97.45 | 5 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $90.20 | 6 | $0 (2018) |
| Lilly USA, LLC | $58.75 | 4 | $0 (2023) |
| Bayer HealthCare Pharmaceuticals Inc. | $55.25 | 2 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $137.11 | 8 | Amgen Inc. ($60.79) |
| 2023 | $190.69 | 9 | Amgen Inc. ($35.04) |
| 2022 | $165.23 | 9 | Astellas Pharma US Inc ($37.71) |
| 2021 | $259.70 | 16 | AbbVie Inc. ($127.95) |
| 2020 | $62.54 | 4 | GlaxoSmithKline, LLC. ($31.79) |
| 2019 | $208.66 | 9 | Janssen Pharmaceuticals, Inc ($82.87) |
| 2018 | $124.52 | 8 | Novartis Pharmaceuticals Corporation ($33.92) |
| 2017 | $221.60 | 12 | AstraZeneca Pharmaceuticals LP ($58.90) |
All Payment Transactions
75 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $22.79 | General |
| Category: RESPIRATORY | ||||||
| 10/14/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $17.11 | General |
| Category: Inflammation | ||||||
| 05/27/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $13.84 | General |
| Category: VACCINES | ||||||
| 05/24/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: Inflammation | ||||||
| 02/26/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $19.31 | General |
| Category: Diabetes | ||||||
| 02/12/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $15.60 | General |
| Category: Inflammation | ||||||
| 01/22/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $13.50 | General |
| Category: Inflammation | ||||||
| 01/09/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $20.38 | General |
| Category: VACCINES | ||||||
| 12/07/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $17.71 | General |
| Category: Inflammation | ||||||
| 10/30/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $17.33 | General |
| Category: Inflammation | ||||||
| 10/05/2023 | GlaxoSmithKline, LLC. | BOOSTRIX (Biological) | Food and Beverage | In-kind items and services | $28.82 | General |
| Category: VACCINES | ||||||
| 10/03/2023 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $23.74 | General |
| Category: VACCINES | ||||||
| 08/22/2023 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Biological | ||||||
| 05/01/2023 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $18.39 | General |
| Category: Diabetes | ||||||
| 04/03/2023 | Lilly USA, LLC | TRULICITY (Drug), MOUNJARO | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: Diabetes | ||||||
| 04/01/2023 | Boston Scientific Corporation | WaveWriter Alpha Prime 16 (Device) | Food and Beverage | In-kind items and services | $30.81 | General |
| Category: WaveWriter Alpha_NMD | ||||||
| 03/02/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/26/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.65 | General |
| Category: Gastroenterology | ||||||
| 10/11/2022 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $22.68 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/10/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $14.32 | General |
| Category: Diabetes | ||||||
| 07/21/2022 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $20.22 | General |
| Category: NEPHROLOGY | ||||||
| 07/21/2022 | Astellas Pharma US Inc | Myrbetriq (Drug) | Food and Beverage | In-kind items and services | $12.99 | General |
| Category: Urology | ||||||
| 05/11/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $11.71 | General |
| Category: Gastroenterology | ||||||
| 04/11/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $12.62 | General |
| Category: Diabetes | ||||||
| 03/17/2022 | Astellas Pharma US Inc | Myrbetriq (Drug) | Food and Beverage | In-kind items and services | $24.72 | General |
| Category: Urology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 271 | 478 | $71,485 | $37,619 |
| 2022 | 9 | 381 | 614 | $86,375 | $44,687 |
| 2021 | 6 | 308 | 543 | $67,046 | $37,103 |
| 2020 | 8 | 305 | 392 | $48,068 | $23,259 |
Total Patients
1,265
Total Services
2,027
Medicare Billing
$142,667
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 148 | 309 | $47,895 | $25,925 | 54.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 65 | 65 | $16,250 | $8,663 | 53.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 32 | 41 | $5,125 | $2,394 | 46.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 13 | 50 | $1,500 | $504.69 | 33.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 13 | 13 | $715.00 | $131.78 | 18.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 165 | 325 | $50,375 | $26,114 | 51.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 89 | 89 | $22,250 | $12,148 | 54.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 39 | 46 | $5,750 | $2,799 | 48.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 14 | 14 | $3,080 | $1,218 | 39.5% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 16 | 16 | $1,600 | $1,124 | 70.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 20 | 70 | $2,100 | $674.09 | 32.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 16 | 16 | $480.00 | $470.40 | 98.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 11 | 11 | $605.00 | $120.44 | 19.9% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2022 | 11 | 27 | $135.00 | $19.12 | 14.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 133 | 252 | $38,941 | $22,895 | 58.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 62 | 62 | $15,500 | $8,619 | 55.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 67 | 82 | $10,050 | $4,752 | 47.3% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 21 | 71 | $2,130 | $789.36 | 37.1% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2021 | 14 | 31 | $155.00 | $31.29 | 20.2% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2021 | 11 | 45 | $270.00 | $16.76 | 6.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 67 | 88 | $13,024 | $7,063 | 54.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 74 | 98 | $14,504 | $6,391 | 44.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 38 | 38 | $9,500 | $4,569 | 48.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 59 | 73 | $7,300 | $3,397 | 46.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 11 | 11 | $1,100 | $628.32 | 57.1% |
About Dr. Larry Hughes, MD
Dr. Larry Hughes, MD is a Adolescent Medicine healthcare provider based in Hemet, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1417033291.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Larry Hughes, MD has received a total of $1,370 in payments from pharmaceutical and medical device companies, with $137.11 received in 2024. These payments were reported across 75 transactions from 21 companies. The most common payment nature is "Food and Beverage" ($1,338).
As a Medicare-enrolled provider, Hughes has provided services to 1,265 Medicare beneficiaries, totaling 2,027 services with total Medicare billing of $142,667. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Adolescent Medicine
- Other Specialties Adult Medicine, Geriatric Medicine
- Location Hemet, CA
- Active Since 10/27/2006
- Last Updated 10/04/2019
- Taxonomy Code 207QA0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1417033291
Products in Payments
- VRAYLAR (Drug) $127.95
- XARELTO (Drug) $102.28
- Otezla (Drug) $95.83
- ENTRESTO (Drug) $79.22
- FARXIGA (Drug) $75.69
- MYRBETRIQ (Drug) $55.36
- Kerendia (Drug) $55.25
- Ozempic (Drug) $52.84
- BOOSTRIX (Biological) $50.89
- TRULICITY (Drug) $45.23
- XIFAXAN (Drug) $40.64
- Myrbetriq (Drug) $37.71
- SHINGRIX (Biological) $34.22
- Tresiba (Drug) $32.27
- TRELEGY ELLIPTA (Drug) $31.79
- WaveWriter Alpha Prime 16 (Device) $30.81
- STIOLTO RESPIMAT (Drug) $26.69
- CHANTIX (Drug) $24.68
- Aimovig (Biological) $24.55
- Prolia (Biological) $24.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.